Could Affymetrix Be Next Takeover in BioHealth? (AFFX, CALP, LIFE, QGEN)
Everyone wants to know which stocks in biotech and medical technology will be the next buyout target. It is rare that research reports or interviews from traditional brokerage firms point out an obvious takeover candidate, but that is exactly what came about in shares of Affymetrix Inc. (NASDAQ: AFFX) this morning. We first saw a move today in the company’s stock options volume on the heels of an analyst’s comments today.
The company is into consumables and systems for genetic analysis in the life sciences and clinical healthcare markets with its integrated GeneChip microarray platform including disposable DNA probe arrays consisting of nucleic acid sequences. It also operates or sells in North America, Europe, Latin America, India, the Middle East, China and the Asia Pacific regions. It has collaboration partnerships with Caliper Life Sciences (NASDAQ: CALP), CapitalBio Corporation, Life Technologies Corporation (NASDAQ: LIFE), Pathwork Diagnostics, and Qiagen (NASDAQ: QGEN). Of these partnerships, Qiagen and Life Technologies are both far larger than Affymetrix.
Read more
